NCT00098540View on ClinicalTrials.gov

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2007

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

sorafenib tosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00098540 - Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter